IP Group (LON:IPO) Releases Earnings Results

IP Group (LON:IPO) issued its quarterly earnings data on Tuesday. The company reported GBX 3.53 earnings per share for the quarter, Digital Look Earnings reports. IP Group had a net margin of 148.78% and a return on equity of 7.14%.

Here are the key takeaways from IP Group’s conference call:

• NAV per share rose 3.2% to 114p at June 30 and approximately 117p by September 11, while gross cash reached about £239 million. Portfolio companies also raised more than £500 million from third parties, providing external validation of their progress.
• Pfizer’s obesity programs continued to de-risk, with the royalty asset’s carrying value increasing by £27 million to roughly £153 million after the amylin combination entered Phase IIb. Berobenatide Phase III recruitment is reportedly close to completion, supporting a potential 2028 launch, although clinical, regulatory and commercial risks remain.
• Cash realizations were strong at £69 million in the first half and approximately £86 million year to date, taking cumulative proceeds since the start of 2025 to £154 million. Management remains confident in reaching its £250 million realization target by the end of 2027.
• Oxford Nanopore reported 12% constant-currency revenue growth, a 400-basis-point gross-margin improvement and an adjusted EBITDA loss that more than halved. It remains on track for EBIT break-even in 2027 and positive free cash flow in 2028, supported by a new cross-licensing agreement with $35 million of committed revenue plus royalties.
• Management acknowledged that the shares continue to trade at roughly a 40% discount to NAV and said reducing the gap will require sustained NAV growth, more realizations and shareholder-focused capital allocation. Around £50 million is available for potential shareholder returns, but the timing and form of any action have not been decided.

IP Group Trading Up 0.4%

Shares of IPO stock opened at GBX 67.60 on Wednesday. The company has a current ratio of 0.16, a quick ratio of 8.59 and a debt-to-equity ratio of 12.28. The stock has a market capitalization of £597.20 million, a price-to-earnings ratio of 9.52 and a beta of 1.27. IP Group has a 12-month low of GBX 48 and a 12-month high of GBX 75. The stock’s 50-day moving average price is GBX 67.74 and its 200-day moving average price is GBX 63.01.

Analyst Ratings Changes

Separately, Berenberg Bank reissued a “buy” rating and set a GBX 119 price target on shares of IP Group in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, IP Group has an average rating of “Buy” and a consensus price target of GBX 114.50.

Insider Activity at IP Group

In other news, insider Michael Queen acquired 200,000 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were acquired at an average cost of GBX 66 per share, with a total value of £132,000. Also, insider David Baynes bought 26,368 shares of the stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of GBX 68 per share, with a total value of £17,930.24. Over the last three months, insiders bought 271,368 shares of company stock valued at $18,053,024. Insiders own 1.57% of the company’s stock.

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK’s largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.